Phenylketonuria Market to Hit US$ 1,230.05 Million By 2030 | Latest Data Insights
September 07, 2023 04:00 ET
|
CONSEGIC BUSINESS INTELLIGENCE PRIVATE LIMITED
New York, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The global Phenylketonuria Market is expected to witness significant growth at a CAGR of 5.2% during the forecast period of 2023-2030. This growth is...
Phenylketonuria Market to Exhibit Significant Growth, Assesses DelveInsight | Key Companies - BioMarin, Synlogic, PTC Therapeutics, Jnana Therapeutics, Homology Medicines
July 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Phenylketonuria Market to Exhibit Significant Growth, Assesses DelveInsight | Key Companies - BioMarin, Synlogic, PTC Therapeutics, Jnana...
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
July 11, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
June 08, 2023 06:45 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will...
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
June 05, 2023 06:45 ET
|
Synlogic, Inc.
Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in...
Global Phenylketonuria Market Size To Grow USD 1121.01 Billion by 2030 | CAGR of 6.2%
April 20, 2023 07:45 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , April 20, 2023 (GLOBE NEWSWIRE) -- The Global Phenylketonuria Market Size is to grow from USD 610.3 million in 2022 to USD 1121.01 million by 2032, at a Compound Annual...
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 29, 2023 06:40 ET
|
Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023 06:55 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 07, 2023 06:57 ET
|
Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
January 19, 2023 06:58 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...